Global Trials Focus
Every month the ISN-ACT Team lists interesting new randomized controlled trials (RCTs) from around the world.
Highlight:
- Corticosteroids and cyclophosphamide may be superior to tacrolimus and rituximab in the treatment of primary membranous nephropathy at the cost of increased adverse events
See the latest trials here.
A summary of the highlighted trial is now available in French, Mandarin, Russian, and Spanish.
Support equal access to nephrology research: Become an ISN Member!
